De vertaling van deze pagina is experimenteel en in ontwikkeling. Uw is welkom!
ResMed Balans Gezondheid
Financiële gezondheid criteriumcontroles 6/6
ResMed heeft een totaal eigen vermogen van $4.9B en een totale schuld van $707.2M, wat de schuld-eigenvermogensverhouding op 14.5% brengt. De totale activa en totale passiva bedragen respectievelijk $6.9B en $2.0B. De EBIT ResMed is $1.4B waardoor de rentedekking 27.8 is. Het heeft contanten en kortetermijnbeleggingen van $238.4M.
Belangrijke informatie
14.5%
Verhouding schuld/eigen vermogen
US$707.21m
Schuld
| Rente dekkingsratio | 27.8x |
| Contant | US$238.36m |
| Aandelen | US$4.86b |
| Totaal verplichtingen | US$2.01b |
| Totaal activa | US$6.87b |
Recente financiële gezondheidsupdates
Does ResMed (NYSE:RMD) Have A Healthy Balance Sheet?
Jul 29
ResMed (NYSE:RMD) Seems To Use Debt Quite Sensibly
Apr 30We Think ResMed (NYSE:RMD) Can Stay On Top Of Its Debt
May 26Recent updates
Why ResMed's Rally Is Just Getting Started
Sep 18ResMed Inc.'s (NYSE:RMD) Earnings Haven't Escaped The Attention Of Investors
Sep 13ResMed (NYSE:RMD) Is Increasing Its Dividend To $0.53
Aug 05Does ResMed (NYSE:RMD) Have A Healthy Balance Sheet?
Jul 29Returns On Capital Are A Standout For ResMed (NYSE:RMD)
Jul 15ResMed: Asymmetrical Value Opportunity With High Prospect Of Re-Rating
Jul 03An Intrinsic Calculation For ResMed Inc. (NYSE:RMD) Suggests It's 33% Undervalued
Jul 02ResMed (NYSE:RMD) Seems To Use Debt Quite Sensibly
Apr 30Earnings Beat: ResMed Inc. Just Beat Analyst Forecasts, And Analysts Have Been Updating Their Models
Apr 30ResMed Inc.'s (NYSE:RMD) Popularity With Investors Is Clear
Apr 18With EPS Growth And More, ResMed (NYSE:RMD) Makes An Interesting Case
Mar 22Capital Investments At ResMed (NYSE:RMD) Point To A Promising Future
Mar 10An Intrinsic Calculation For ResMed Inc. (NYSE:RMD) Suggests It's 30% Undervalued
Feb 12Why ResMed Is One Of My Top Picks In 2024
Jan 22A First Look At ResMed
Jan 09ResMed Inc.'s (NYSE:RMD) Share Price Could Signal Some Risk
Dec 20Why You Should Care About ResMed's (NYSE:RMD) Strong Returns On Capital
Dec 06Shareholders May Find It Hard To Justify Increasing ResMed Inc.'s (NYSE:RMD) CEO Compensation For Now
Nov 10Are Investors Undervaluing ResMed Inc. (NYSE:RMD) By 41%?
Nov 01ResMed: Weight-Loss Drug Worries Provide Buying Opportunity
Oct 28ResMed: Stock Re-Rating To 20x Forward P/E Is A Buy Opportunity
Sep 12ResMed Has Become A Steal (Rating Upgrade)
Aug 10ResMed's (NYSE:RMD) Shareholders Will Receive A Bigger Dividend Than Last Year
Aug 07ResMed (NYSE:RMD) Has Some Way To Go To Become A Multi-Bagger
Jul 30Here's Why We Think ResMed (NYSE:RMD) Might Deserve Your Attention Today
Jul 16Compound Your Wealth With ResMed
Jul 04A Look At The Fair Value Of ResMed Inc. (NYSE:RMD)
Jul 02We Think ResMed (NYSE:RMD) Can Stay On Top Of Its Debt
May 26ResMed (NYSE:RMD) Could Be Struggling To Allocate Capital
Apr 24Here's Why ResMed (NYSE:RMD) Has Caught The Eye Of Investors
Apr 09A Look At The Intrinsic Value Of ResMed Inc. (NYSE:RMD)
Mar 26Analyse van de financiële positie
Kortlopende schulden: De korte termijn activa ( $2.4B ) RMD } overtreffen de korte termijn passiva ( $910.7M ).
Langlopende schulden: De kortetermijnactiva RMD ( $2.4B ) overtreffen de langetermijnschulden ( $1.1B ).
Schuld/ eigen vermogen geschiedenis en analyse
Schuldniveau: De netto schuld/eigen vermogen ratio ( 9.6% ) RMD wordt als voldoende beschouwd.
Schuld verminderen: De schuld/eigen vermogen-ratio van RMD is de afgelopen 5 jaar gedaald van 61.3% naar 14.5%.
Schuldendekking: De schuld van RMD wordt goed gedekt door de operationele kasstroom ( 198.1% ).
Rentedekking: De rentebetalingen op de schuld van RMD worden goed gedekt door EBIT ( 27.8 x dekking).